NFKB1 and Cognitive impairment: In our investigation, the addition of an AMPK inhibitor, Compound C, resulted in cognitive impairment in TBI rats, which was improved following high-dose UCF-101, further supporting the moderating influence of the AMPK/NF-κB signaling pathway in the neurological damage recovery of UCF-101 treatment for TBI rats.